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access. Thus, in this controlled trial, following induction 
with 14 days of IV ganciclovir (6mg/kg IV qd), CMV- 
seronegative liver transplant recipients with CMV-sero- 
positive donors were randomized to receive either 
oral ganciclovir (1000 I mg 18hrs, Mon-Sun) or IV 
ganciclovir (6 mg/kg qd, Mon-Fri) until day 100 after 
transplant. Patients were followed until time of death or 
12 months after transplant. CMV disease occurred in 
3/32 oral ganciclovir patients (9.3%) and in 4/32 IV 
ganciclovir patients (12S%).Types of CMV disease: oral 
ganciclovir (syndrome 2, hepatitis 1); IV ganciclovir 
(syndrome 3, hepatitis + colitis l).There were no deaths 
from CMV in either study group. All cases of CMV 
disease occurred > 90 days after transplant (median time 
of onset day+137 for oral ganciclovir and day+135 for 
IV ganciclovir). Both oral and IV ganciclovir were well- 
tolerated. Reversible leukopenia (WBC <3000/mm3) 
occurred in 9/32 oral ganciclovir patients (28.1%) and in 
12/32 IV ganciclovir patients (37.5%) but did not require 
withdrawal of any patient from the study. Emergence of 
ganciclovir-resistant strains of CMV was not found 
during the study. These results suggest that, following 
induction with 2 weeks of IV ganciclovir, oral ganciclovir 
can be as effective as IV ganciclovir for long-term CMV 
prophylaxis in high-risk CMV-seronegative liver 
transplant patients with CMV-seropositive donors and 
eliminate the need for prolonged IV access. 
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Two hundred and sixteen HD patients (M:102, F:114, 
aged 4517212.84) received recombinant hepatitis B 
vaccine (Combiotech Ltd, Russia) or Engerix B. The 
protocol of vaccination scheduled 4 doses of 40 Kg at O- 
l-2-6 months. Before the end of vaccination 13 pts (6%) 
had acute hepatitis B. HBsAb levels in this group was 
~100 IU/L after the 3 mos. 27 pts (13%) at the end of 
vaccination had HBcoreAB. The efficacy of vaccination 
was evaluated by the determination HBsAb levels after 
3 and 7 mos from the beginning of immunization in 176 
pts.The frequency of seroconversion (HBsAb level from 
10 to 99 IU/L) after 3mos was 23% and it was 13% after 
7 mos. The rate of seroprotection (HBsAb level 2100 
IU/L) after 3 mos reached 50% and increased up to 70% 
after 7 mos. Relation between some factors involved in 
immune response and vaccination efficiency in 46 pts 
was studied. In patients with HBsAb level ~100 IU/l 
count CD3 lymphocytes were 0.84+0.1 109/1, CD20- 
0.36+0.04 109/1, and concentration of IL-l-2.78+0.63 
pmol/ml, IL-2 -13.36+ 1.97 pmol/ml, IgM - 0.84+0.14 g/l. 
In patients with HBsAb levels 2100 IU/l these values 
were significantly different (~~0.05) and were equal to 
0.9520.16 109/1, 0.41?0.05 109/1, 3.22kO.77 pmol/ml, 
15.9623.2 pmollml, 1.120.24 g/l, respectively. Logistic 
regression analysis and criteria tables method permitted 
to determine the predictors of low efficacy of 
vaccination in HD patients: amount CD20 lymphocytes 
<3.5(109/~, concentration IgM +0.95 rr/rr, IL-2 512 
pmol/ml, transferrin in blood >2.8 g/L. The presence of 
two and more from these parameters allows the 
prognosis of negative or low response to vaccination. 
Sensitivity and specificity of such prognosis equal 86% 
and 84%, respectively. 
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Introduction: Systemic infections due to Listeria 
monocytogenes are infrequent but serious complications 
in patients with an underlying malignancy. Institution of 
appropriate therapy is critical in improving outcome 
especially in patients with profound defects in cellular 
immunity. 
Methods: In vitro antimicrobial susceptibility profiles of 
84 clinical isolates of L. monocytogenes from patients 
with listeric infections during 1955 to 1997 at Memorial 
Sloan-Kettering Cancer Center in New York were 
reviewed retrospectively. 
Results: The 84 L. monocytogenes isolates showed 
greater than ninety percent in vitro susceptibility to 
penicillin (97.6%) ampicillin (90.7%) erythromycin 
(98.8%) tetracycline (96.9%), and gentamicin (98.0%). 
No in vitro resistance was observed for trimethoprim- 
sulfamethoxazole (TMP-SMX), rifampin, amikacin, 
vancomycin, imipenem/cilastatin, and ciprofloxacin. 
High-level resistance to clindamycin (96.2%) and 
amoxicillin/clavulanate (100%) was unexpected. The 
MI& and MIC9o among 26 L. monocytogenes during 
1991 to 1997 for penicillin and ampicillin were 0.5 and 
1.0 kg/ml respectively. During this period MI&, for 
gentamicin, imipenem/cilastatin, and ciprofloxacin was 
5 1.0 Fg/ml. 
Conclusions: Since 1955, we observed no interval in- 
crease in resistance for penicillin, ampicillin, gentamicin 
and TMP-SMX among L. monocytogenes in our high- 
risk listeric patients. Amoxicillin/clavulanate does not 
appear to be an adequate choice for oral therapy in this 
setting. The newer antimicrobial compounds such as 
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carbipenems and fluorinated quinolones need clinical 
validation; however, in vitro susceptibility profile appears 
promising. 
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In eubacteria Escherichia coli and Bacillus subtilis, the 
glpTQ operon is involved in utilization of glycerol3- 
phosphate (G3P) as a carbon source, and the glpT and 
glpQ genes transcribe as a single unit. In Haemophilus 
influenzae, we have previously characterized the glpT 
and glpQ homologues encoding glycerol-3-phosphate 
permease and glycerophosphodiester phosphodiesterase, 
respectively. The protein encoded by glpQ is also called 
Protein D and is involved in pathogenesis. In this study, 
we analysed the glpTQ transcripts in one H. injluenzae 
type b (Hib) and one nontypeable (NTHi) strain, and 
characterized potential function of the 1.4 kb glpTQ 
intergenic region that exists in most Hib strains but not 
in NTHi strains. In Northern blot and RT-PCR analysis, 
the glpT and glpQ genes in the Hib strain transcribed 
separately, whereas a co-transcribed glpTQ was found in 
the NTHi strain. It suggests that the 1.4 kb glpTQ 
intergenic region in Hib strains partially blocks the 
glpTQ operon transcription. When an isogenic mutant 
strain where the 1.4 kb region was replaced with 
a kanamycin cassette in the chromosome of the wild- 
type strain was tested, the blockage of the glpTQ 
transcription disappeared. We therefore conclude that 
due to the existence of the 1.4 kb glpTQ intergenic 
region in Hib strains, the glpTQ operons between Hib 
and NTHi strains transcribed differently. Based on a 
much lower G+C content (26 %) of the 1.4 kb DNA 
coding region than an overall G+C content of 38 % for 
the H. influenzae genome, we speculate that the 1.4 kb 
region might have been acquired by lateral transfer from 
an organism with a lower G+C content. 
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Background: The aim of this open, uncontrolled study 
was to evaluate the reliability of IL for the treatment of 
microbiologically proven, uncomplicated CRBSI, in 
different categories of immunocompromised patients. 
Methods: IL is based on a daily intraluminal instillation 
of a pre-definite highly concentrated solution of 
antimicrobials into the colonized line, locked within the 
line for at least 12 hrs/day Then the solution is removed 
and the CVC eventually re-used. In our study locks 
were repeated along 14 days. Vancomycin or teicoplanin 
20 mg/ml were delivered for empirical locks, or in the 
presence of staphylococci, enterococci, micrococci and 
corynebacteria; amikacin 10 mg/ml or ciprofloxacin 2 
mg/ml for susceptible Gram-negative bacteria; tailored 
antimicrobials for Gram-negative with different patterns 
of chemosensitivity. Fungal CRBSI were excluded. 23 
patients, who had signs and symptoms of uncomplicated 
CRBSI, according to defined criteria, with AIDS (14) 
or haematological neoplasias (9) and carrying long-term 
central venous catheter (CVC) (tunnelled or totally im- 
plantable), were consecutively enrolled. Per protocol, 
they were all given locks plus systemic antimicrobial 
therapy during the first 48 hrs. After this time, once 
microbiological diagnosis had been proven, clinical 
reassessment was performed. If defervescence of fever 
occurred, the patient continued receiving IL alone or in 
combination with systemic therapy (same antimicrobials 
used for locks), according to the clinician’s decision. 
Results: Twelve underwent locks alone and 11 locks plus 
systemic therapy thereafter. 21/23 pts (91.3%) were 
cleared from infection and retained the line in place: 
12/12 in the IL arm and 9/11 in the IL plus systemic 
therapy arm, as of clinical and microbiological follow-up 
performed at 14 days after the completion of treatment. 
The only two failures occurred in the combined treatment 
arm and were due to polymicrobial infections (methi- 
cillin-resistant Staphylococcus aureus plus Gram-negative 
bacteria), treated with glycopeptide alone-based locks. 
Conclusions: This study, though limited, confirms that 
IL is an effective treatment option also for immuno- 
compromised patients. Furthermore IL alone seems to 
be at least as effective as IL plus systemic therapy in 
the treatment of uncomplicated CRBSI, for the high 
antimicrobial concentrations obtained directly within 
the site of infection; but it results also in negligible blood 
antimicrobial concentrations, thus limiting the risk of 
dose-dependent side-effects and making it appealing in 
pts with liver or renal impairment as well. 
Trends in spectrum and susceptibility patterns of 
pathogens causing bacteremia in pediatric febrile 
neutropenic oncologic patients (1998-2002) 
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Background: Prospective surveillance of resistant 
bacterial pathogens is an indispensable tool of quality 
control in pediatric oncology departments. 
